Browse the evidence

Incretin-based therapies lead to reduced ectopic fat depositions in multiple organs and favourable cardiac remodelling.

Incretin-based therapies may be effective in reducing harmful fat deposits and improving heart structure in affected patients.

Metabolic and bariatric surgery (MBS) achieves superior comorbidity remission compared to intensive medical therapy.

MBS should be considered as a primary treatment option for patients with severe obesity and related comorbidities.

Laparoscopic Roux-en-Y gastric bypass provides superior long-term remission of dyslipidaemia, hypertension, and gastro-oesophageal reflux disease compared to laparoscopic sleeve gastrectomy.

Surgeons should consider Roux-en-Y gastric bypass for patients with specific comorbidities.

Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).

Incorporating exercise counseling may enhance weight maintenance outcomes for patients after GLP-1RA therapy.

Preliminary dose-dependent weight reductions were observed with KN069.

KN069 may help in achieving weight loss in this demographic.

KN069 led to significant metabolic improvements including lower fasting glucose and triglycerides.

KN069 may improve metabolic health markers in this population.

GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.

Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.

GLP-1 RAs demonstrate multisystemic benefits including cardiovascular risk reduction and improved renal outcomes.

Incorporating GLP-1 RAs in treatment plans may enhance overall patient health beyond weight loss.

Surgeons should recognize GLP-1 RAs as complementary tools within multidisciplinary obesity and metabolic care pathways.

Surgeons should integrate GLP-1 RAs into their treatment strategies for obesity management.

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

64.8% of patients with obstructive sleep apnea (OSA) presenting to a sleep surgery clinic met FDA-approved criteria for GLP-1 receptor agonist (RA) use.

Practitioners should consider that a significant portion of OSA patients may be eligible for GLP-1 RA treatment.

GLP-1 RA use was associated with significantly lower rates of re-tear (RR = 0.699, p < 0.001).

Practitioners may consider GLP-1 RAs as beneficial for reducing re-tear rates in rotator cuff repair patients.

The DRL agent achieved a prediction accuracy of optimal doses of 92%, exceeding traditional models by 15%.

The DRL agent can provide more accurate dosing recommendations compared to traditional methods.

In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.

Retatrutide may improve glycemic control in patients with type 2 diabetes.

Retatrutide achieves an 82.4% relative reduction in hepatic fat and normalizes liver fat in 86% of patients.

Retatrutide may be beneficial for patients with fatty liver disease.

Tirzepatide treatment preserved lean mass and muscle function after 4 months.

Tirzepatide may help maintain muscle mass and function during weight loss in obese patients.

Whey and soy proteins can be part of a resistance training regimen, but findings should be interpreted with caution due to small sample size.

Practitioners should consider the potential benefits of protein supplementation while being aware of the limitations of the current evidence.

There was no significant clinical aggravation of renal biomarkers in the studies reviewed.

Clinicians can be reassured that protein supplementation does not adversely affect renal biomarkers in this population.

The existing data on protein supplementation and kidney function is weakened by brief study periods and traditional biomarkers.

Future research should focus on longer study durations and advanced renal markers for better safety profiles.

Dysfunctional eating attitudes and behaviors (DEAB) are more concerning in the athletic population than in the general population.

Practitioners should be aware that athletes may exhibit higher levels of dysfunctional eating behaviors compared to non-athletes.

There is a need for assessment tools specifically adapted to the context of athletes to improve screening accuracy for DEAB.

Developing and validating tailored assessment tools can enhance the identification of DEAB in athletes.